Antidepressants and risk of dementia in migraine patients: A population-based case-control study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 77, Issue , 2017, Pages 83-89

  Lee, Cynthia Wei Sheng ^a   Lin, Cheng Li ^a,b   Lin, Pan Yen ^a,b   Thielke, Stephen ^c   Su, Kuan Pin ^a,b   Kao, Chia Hung ^a,b,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

Antidepressants; Case control study; Dementia; Migraine; SSRI; Tricyclic

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; POPULATION BASED CASE CONTROL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; CASE CONTROL STUDY; CHEMICALLY INDUCED; FACTUAL DATABASE; MIDDLE AGED; TAIWAN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; TAIWAN;

EID: 85017363309     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2017.04.006     Document Type: Article

References (39)

1. Treatment Guideline Subcommittee of the Taiwan Headache Society, Treatment guidelines for preventive treatment of migraine. Acta Neurol. Taiwanica 17 (2008), 132–148.
2. National Health Insurance Research Database, Taiwan, Available from: http://nhird.nhri.org.tw/en/index.html, 2015.
3. Abrahamowicz, M., Bjerre, L.M., Beauchamp, M.E., LeLorier, J., Burne, R., The missing cause approach to unmeasured confounding in pharmacoepidemiology. Stat. Med. 35 (2016), 1001–1016.
4. Ascher, J.A., Cole, J.O., Colin, J.N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., Golden, R.N., Martin, P., Potter, W.Z., Richelson, E., Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56 (1995), 395–401.
5. Bymaster, F.P., Lee, T.C., Knadler, M.P., Detke, M.J., Iyengar, S., The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des. 11 (2005), 1475–1493.
6. Carvalho, A.F., Miskowiak, K.K., Hyphantis, T.N., Kohler, C.A., Alves, G.S., Bortolato, B., Sales, P.M., Machado-Vieira, R., Berk, M., McIntyre, R.S., Cognitive dysfunction in depression - pathophysiology and novel targets. CNS Neurol. Disord. Drug Targets 13 (2014), 1819–1835.
7. Cherbuin, N., Kim, S., Anstey, K.J., Dementia risk estimates associated with measures of depression: a systematic review and meta-analysis. BMJ Open, 5, 2015, e008853.
8. Chuang, C.S., Lin, C.L., Lin, M.C., Sung, F.C., Kao, C.H., Migraine and risk of dementia: a nationwide retrospective cohort study. Neuroepidemiology 41 (2013), 139–145.
9. Diener, H.C., Charles, A., Goadsby, P.J., Holle, D., New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 14 (2015), 1010–1022.
10. Haddjeri, N., Blier, P., de Montigny, C., Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int. Clin. Psychopharmacol. 10 (1995), 11–17.
11. Han, L., Kim, N., Brandt, C., Allore, H.G., Antidepressant use and cognitive deficits in older men: addressing confounding by indications with different methods. Ann. Epidemiol. 22 (2012), 9–16.
12. Herrera-Guzmán, I., Herrera-Abarca, J.E., Gudayol-Ferré, E., Herrera-Guzmán, D., Gómez-Carbajal, L., Peña-Olvira, M., Villuendas-González, E., Joan, G.O., Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 177 (2010), 323–329.
13. Hoirisch-Clapauch, S., Nardi, A.E., Gris, J.C., Brenner, B., Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?. Thromb. Res. 134 (2014), 11–16.
14. Holroyd, K.A., Bendtsen, L., Tricyclic antidepressants for migraine and tension-type headaches. BMJ, 341, 2010, c5250.
15. Huang, X., Mao, Y.S., Li, C., Wang, H., Ji, J.L., Venlafaxine inhibits apoptosis of hippocampal neurons by up-regulating brain-derived neurotrophic factor in a rat depression model. Int. J. Clin. Exp. Pathol. 7 (2014), 4577–4586.
16. Iadecola, C., The pathobiology of vascular dementia. Neuron 80 (2013), 844–866.
17. Keowkase, R., Aboukhatwa, M., Luo, Y., Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59 (2010), 358–365.
18. Kessing, L.V., Forman, J.L., Andersen, P.K., Do continued antidepressants protect against dementia in patients with severe depressive disorder?. Int. Clin. Psychopharmacol. 26 (2011), 316–322.
19. Kessing, L.V., Sondergard, L., Forman, J.L., Andersen, P.K., Antidepressants and dementia. J. Affect. Disord. 117 (2009), 24–29.
20. Kim, H.K., Nunes, P.V., Oliveira, K.C., Young, L.T., Lafer, B., Neuropathological relationship between major depression and dementia: a hypothetical model and review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 67 (2016), 51–57.
21. Lauterbach, E.C., Shillcutt, S.D., Victoroff, J., Coburn, K.L., Mendez, M.F., Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications. J. Neuropsychiatr. Clin. Neurosci. 22 (2010), 130–154.
22. Lauterbach, E.C., Victoroff, J., Coburn, K.L., Shillcutt, S.D., Doonan, S.M., Mendez, M.F., Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J. Neuropsychiatr. Clin. Neurosci. 22 (2010), 8–18.
23. Lee, C.W., Lin, C.L., Sung, F.C., Liang, J.A., Kao, C.H., Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study. J. Clin. Psychiatry 77 (2016), 117–122.
24. Luo, P., Zhang, X., Lu, Y., Chen, C., Li, C., Zhou, M., Lu, Q., Xu, X., Shen, G., Guo, L., Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats. Pharmacol. Biochem. Behav. 140 (2016), 1–7.
25. Meulendyke, K.A., Queen, S.E., Engle, E.L., Shirk, E.N., Liu, J., Steiner, J.P., Nath, A., Tarwater, P.M., Graham, D.R., Mankowski, J.L., Zink, M.C., Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J. Neuro-Oncol. 20 (2014), 591–602.
26. Mohs, R., Mease, P., Arnold, L.M., Wang, F., Ahl, J., Gaynor, P.J., Wohlreich, M.M., The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosom. Med. 74 (2012), 628–634.
27. Pacher, P., Kecskemeti, V., Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr. Pharm. Des. 10 (2004), 2463–2475.
28. Parsons, L.S., Performing a 1:N case-control match on propensity score. Proceedings of the 29th Annual SAS Users Group International Conference, 2004, SAS Institute, Cary, NC.
29. Patten, S.B., Confounding by severity and indication in observational studies of antidepressant effectiveness. Can. J. Clin. Pharmacol. 15 (2008), e367–e371.
30. Peng, Y.C., Lin, C.L., Hsu, W.Y., Chang, C.S., Yeh, H.Z., Tung, C.F., Wu, Y.L., Sung, F.C., Kao, C.H., Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study. Br. J. Clin. Pharmacol. 80 (2015), 755–761.
31. Raskin, J., Wiltse, C.G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J.J., Rotz, B.T., Mohs, R.C., Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 164 (2007), 900–909.
32. Ren, Q.G., Wang, Y.J., Gong, W.G., Zhou, Q.D., Xu, L., Zhang, Z.J., Escitalopram ameliorates Forskolin-induced tau hyperphosphorylation in HEK239/tau441 cells. J. Mol. Neurosci. 56 (2015), 500–508.
33. Sas, K., Pardutz, A., Toldi, J., Vecsei, L., Dementia, stroke and migraine – some common pathological mechanisms. J. Neurol. Sci. 299 (2010), 55–65.
34. Sheline, Y.I., West, T., Yarasheski, K., Swarm, R., Jasielec, M.S., Fisher, J.R., Ficker, W.D., Yan, P., Xiong, C., Frederiksen, C., Grzelak, M.V., Chott, R., Bateman, R.J., Morris, J.C., Mintun, M.A., Lee, J.M., Cirrito, J.R., An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci. Transl. Med., 6, 2014, 236re234.
35. Stagni, F., Giacomini, A., Guidi, S., Ciani, E., Ragazzi, E., Filonzi, M., De Iasio, R., Rimondini, R., Bartesaghi, R., Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. Neurobiol. Dis. 74 (2015), 204–218.
36. Uddin, M.J., Groenwold, R.H., Ali, M.S., de Boer, A., Roes, K.C., Chowdhury, M.A., Klungel, O.H., Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. Int. J. Clin. Pharm. 38 (2016), 714–723.
37. Wang, C., Gao, S., Hendrie, H.C., Kesterson, J., Campbell, N.L., Shekhar, A., Callahan, C.M., Antidepressant use in the elderly is associated with an increased risk of dementia. Alzheimer Dis. Assoc. Disord. 30 (2016), 99–104.
38. Wang, S.J., Chen, P.K., Fuh, J.L., Comorbidities of migraine. Front. Neurol., 1, 2010, 16.
39. Yekehtaz, H., Farokhnia, M., Akhondzadeh, S., Cardiovascular considerations in antidepressant therapy: an evidence-based review. J. Tehran Heart Cent. 8 (2013), 169–176.